The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Nov. 28, 10:37 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #86. AstraZeneca Omthera

Acquirer: AstraZeneca (AZN)
Acquiree: Omthera (OMTH)
Details: The stockholders of Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) (the "Company") voted today at a special meeting of stockholders to adopt the previously announced merger agreement providing for the acquisition of the Company by an affiliate of AstraZeneca PLC. The votes cast by the Company's stockholders in favor of the proposal to adopt the merger agreement represented approximately 88.3 percent of the Company's issued and outstanding common stock entitled to vote as of June 13, 2013, the record date for the special meeting.

AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business focusing on the research, development and commercialization of prescription medicines. Co. focuses on disease areas that include Oncology; BioPharmaceuticals; Rare Disease; and Other Medicines and COVID-19. Key marketed products within the area of oncology include among other, Tagrisso (osimertinib) for lung cancer and Lynparza (olaparib) for ovarian cancer. Key marketed products within the area of Other Medicines and COVID-19 include among other, Synagis (palivizumab) for respiratory syncytial virus; and Evusheld (tixagevimab co-packaged with cilgavimab) for COVID-19.

Open the AZN Page at The Online Investor »

AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business focusing on the research, development and commercialization of prescription medicines. Co. focuses on disease areas that include Oncology; BioPharmaceuticals; Rare Disease; and Other Medicines and COVID-19. Key marketed products within the area of oncology include among other, Tagrisso (osimertinib) for lung cancer and Lynparza (olaparib) for ovarian cancer. Key marketed products within the area of Other Medicines and COVID-19 include among other, Synagis (palivizumab) for respiratory syncytial virus; and Evusheld (tixagevimab co-packaged with cilgavimab) for COVID-19.

Open the OMTH Page at The Online Investor »

Company Name: 
AstraZeneca Plc
Website: 
www.astrazeneca.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding AZN: 
13
Total Market Value Held by ETFs: 
$763.59M
Total Market Capitalization: 
$32.56B
% of Market Cap. Held by ETFs: 
2.35%
Company Name: 
Omthera Pharmaceuticals, Inc
Website: 
www.omthera.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 86 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.